Good day ladies and gentlemen and welcome to the Arcturus Therapeutics Third Quarter 2022 Earnings Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Kyle Gutsadt, Senior Analyst, Investor & Public Relations. Please go ahead, sir.

Thank you, Keith. Good afternoon and welcome to Arcturus Therapeutics third quarter 2022 financial update and pipeline progress call. Thank you all for joining us. Today’s call will be led by Joseph Payne, our President and CEO; and Andy Sassine, our CFO. Dr. Pad Chivukula, our CSO and COO, will join in for the Q&A session. Before we begin, I would like to remind everyone that, statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the company’s press release issued earlier today, as well as the risk factors section in our Forms 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made, May 9, 2022. Arcturus specifically disclaims any obligation to update such statements to reflect future information, events or circumstances. And with that, I will now turn the call over to Joe.

Thank you and good afternoon to all. Thank you for joining our tourist’s Q3 quarterly call. The recent period has been characterized by remarkable progress we have made both with our pipeline and also in completing transformational business development agreements with CSL and BARDA. I will begin with our recently announced collaboration with CSL. I want to first express my gratitude to the entire team here at Arcturus that worked tirelessly on this deal, particularly the deal team led by Lance Carta, our Chief Legal Officer and Kevin Skull, who leads our Business Development Efforts. They all did an exceptional job. Indeed, there is an extraordinary story behind every extraordinary deal, so thank you to the team, many of which are listening to the call. This collaboration with CSL is designed to develop and commercialize self amplifying mRNA vaccines targeting COVID-19, influenza, three additional pathogens and pandemic preparedness. This broad strategic collaboration will drive the development, manufacturer and global commercialization of novel self amplifying mRNA based vaccines. This was a transformative deal for Arcturus, both from a financial perspective as well as in positioning our company to become a leader in the development and delivery of mRNA Vaccines and Therapeutics. CSL Seqirus is one of the top two companies in the multiple billion dollar influenza vaccine market, and they bring profound capabilities, especially related to advanced vaccine manufacturing, development, distribution, and commercialization. The collaboration combines CSL Seqirus, well established global vaccine, commercial and manufacturing infrastructure with our tourist’s manufacturing expertise in innovative star self amplifying mRNA vaccine and LUNAR delivery platform technologies. Together, we will focus on the development of self amplifying mRNA vaccines targeting COVI-19, influenza, three, additional defined respiratory infectious disease vaccines and pandemic preparedness, and we look forward to providing continued updates on our plans and progress…

Thank you, Joe, and good afternoon, everyone. The press release issued earlier today includes financial statements with a third quarter of 2022 and provides a summary and analysis of year over year and sequential financial performance. Please reference our 10-Q for more details on the financial performance. I will begin with a summary of the CSL agreement we signed last week. Under the terms of the agreement, Arcturus will receive 200 million upfront and is eligible to receive over 1.3 billion in development milestone and over $3 billion in commercial milestones. In addition, the company is eligible to receive a 40% net profit share for COVID-19 vaccine products and up to double-digit royalties for vaccines against flu, pandemic preparedness, and three other respiratory pathogens. This is a 60/40 profit sharing agreement on COVID-19 vaccine product, and with respect to the program cost, we expect the milestones will cover all of our expenses going forward. We provided CSL some R&D credits, which are spread out over five years and will likely be applied to the flu and other programs. CSL transaction is subject to filing under the Harsco Rodino Antitrust Act. The HSR filings have been made by both parties and we are in the waiting period. Assuming the transaction closes and we receive the 200 million upfront payment, we expect that Arcturus will be funded for three-years based on our current pipeline, and assuming no revenues from any product sales. Let assume the milestones will cover all of our COVID program costs. In evaluating new collaborations, we take a comprehensive view of new potential agreements and how they align with our existing agreements to ensure that our plan support our longer-term strategy to advance our pipeline and create shareholder value. Last week then Vinbiocare and our tourists mutually terminated our…

Thanks, Andy. We are highly encouraged about the potential of our mRNA vaccine and therapeutic pipeline, we are very pleased with our recent progress. This recent period has been highlighted by the closing of meaningful agreements and continued advancement of our pipeline of mRNA vaccines and therapeutics. We believe our agreement with CSL Seqirus opens enormous opportunities for our company, and we are excited to continue to execute on our mission to bring meaningful new treatments to patients, while also rewarding our shareholders. We look forward to providing you with future updates on our progress, and I will now turn the call back to the operator for questions.

Thank you. [Operator Instructions] We will take our first question from Yasmeen Rahimi with Piper Sandler. Please go ahead.

Hi team, this is [Lauren] (Ph) on for Yaz. Just two quick questions for you. The first, can you provide some color on the timing for the interim analysis and what exactly will be included in that interim? And then second, how far are you away from filing the CF program in the U.S. and what is left in regard to the CTA? Thanks.

Sure. So the first question are you referring to ARCT-154 or ARCT-810?

The 810.

Okay the 810. We indicated that, we are going to strategically share that data simultaneously or concurrently with the announcement of our new liver therapeutic programs. And so that is going to be sometime in 2023. Of course, we are disappointed with the progress of our recruitment this year. However, we fully intend not to repeat some of those challenges that we have incurred this year. And we look forward to getting the data as soon as we can next year. But what is important to understand is there is going to be a strategic communication of the - communicating the data, the interim data that will be concurrent or simultaneous to the disclosure or declaration or announcement of additional liver therapeutic programs. And the second question is around the CTA. Now there is very little left remaining to do. We indicated that we remain on track for a filing of that CTA this year, this quarter, so that there is not many weeks left. So anything to add pad with respect to the final remaining elements? It is just the application process, the drafting, yes. So all the work has been done and we are just in the process of drafting the filing. That is it.

Perfect. Thank you so much.

We will take our next question from Seamus Fernandez with Guggenheim. Please go ahead.

Thanks for the questions guys. So can you just maybe help us to understand how it sounds like most of the communications for the COVID program are going to be rolling from CSL. Just hoping to get a better understanding of how you guys are working towards in that process. How the reimbursement for R&D expenses given the sort of 40% profit sharing agreement, how that is going to work. I just want to get a better sense of what the timelines for communication around the 154 program might be and what kind of - is written into the contract for you guys to at least influence that on the margin. And then the second question at the R&D event that CSL posted recently, they did talk about their own self amplifying mRNA program. Just wondering if you guys have rights to that program, should that program advance or if your own influenza program and theirs may in fact be competing? Thanks.

Sure, sure. There is a few questions there. I will address them one at a time. First of all, it is correct that CSL is responsible for providing guidance and updates pertaining to ARCT-154 and any of its future derivatives. But we are actively supporting them and working with them on the clinical efforts and regulatory efforts. With respect to the question on any sort of CSL flu development programs, if CSL uses Acrturus’ technology or its platform or manufacturing knowhow in any way, that will trigger the financials for that program, meaning, the associated milestones and royalties. Now there was a question about the 40/60 or the 60/40 ratio. I don’t know if you wanted to elaborate on that, and I can turn that to Andy. But did I address the two major questions?

Yes, you did. Thank you.

We will take our next question from Yigal Nochomovitz with Citi. Please go ahead.

Hi, John, Andy. How are you? Just a few questions here. This is sort of forward-looking and you may not have all the answers obviously. But with the CF program, what is the envision target profile there. I mean, are you thinking this is going to be a daily, a weekly, a monthly inhaled? I know it is very early, but if you have a hypothesis or a vision for what kind of profile you are looking to achieve?

Yes. So what we understand is that, we will be able to express the protein CFTR shortly after administration. But what we also recognize is that, protein does not have a very long half life. However, the effect, the functional effect of that protein may extend the durability of it. And that is still being determined by the field. So how often these treatments will be is speculative at this point. We are anticipating weekly, but we do not know that detail until we collect the data.

Okay got it. And then also a clinical question on OTC. In terms of what you want to see on ammonia reduction to achieve proof concept, what is your threshold there that you are looking to achieve?

Yes, thankfully the field is maturing. Its understanding of what sort of restoration of the enzyme is required for normal function. And we have seen that in analysis and publications that have been shared, that it ranges from four to 16%. So if there is 4% protein restoration that is viewed as preventing death, which would be very meaningful in this disease, especially in young males. And then all the way up to 16% protein restoration would be required for or expected to establish normality in general.

Okay got it. And then, I don’t know if you can answer this one. It might be more of a CSL question, but I think in the CSL press release they mentioned that they are starting program with their own - flu vaccine next year. So, is your flu vaccine that they might work on going to be a parallel program or a backup program, or how does that all work?

Yes. I think it is best to say that we are combining our efforts on this program. Whatever comes out of it a combined or one of the either programs is successful, as long as it uses a portion of our technology or manufacturing knowhow, it will trigger the full financials of milestones and subsequent royalty. But with respect to which of these programs are ultimately going to be selected to move forward in advanced development, we refer you to CSL.

Okay. Thank you.

We will take our next question from Pete Stavropoulos with Cantor Fitzgerald. Please go ahead.

I have one quick question on the OTC program. It is more of a so, when you think about the patient population and the heterogeneity know in terms of presentation the neonatal and the late onset OTC, as well as other programs in development, such as gene therapies. Assuming 810 achieves the target product profile, you hope for how and where do you sort of see this fitting into the evolving treatment landscape?

There is significant advantages to the Arcturus Therapeutic candidate for OTC being a messenger RNA therapeutic. It is a transient effect, which means that any side effects that are observed would also be transient in nature. There is flexibility and attenuate ability of the dosing. There is a wide variety of presentation in this disease so that in some cases it may require lower or higher dosing and adjusted adjustable dosing there. And that is something that this provides. We also lack steroid co-treatment at least so far with respect to this therapeutic candidate. And this is a potentially a considerable advantage especially in the OTC deficiency community. So we bring forward all of those elements. And then Pad, anything else to add?

One other point is that when this is a neonatal disease, so going after the younger kids we think a protein replacement with an mRNA is ideal solution.

Correct. Versus the other options out there.

Yes. So, I guess, part of that neonatal OTC patients usually need a liver transplant from my understanding. So do you view this more as a replacing that need for liver transplant or as a bridging agent?

Both, depending on the age of the participant and the data that we collect as throughout the next year will help guide those decisions. But absolutely the full intent is to replace any need for protein or, I mean, for liver transplant and establish normalcy and really be a disruptive medicine. But in some cases it may be used as a bridge just to extend life to get you to the next stage of therapy.

Okay. And can you provide any color on near-term milestones from the CSL agreement?

I will let Andy address that. We did mention that there is 1.3 billion in development milestones across five targets, but Andy.

Yes. We are not going to give specific to near-term, because what we have articulated is that the COVID-19 programs are going to be covered by the milestones. So that certainly will extend our runway significantly. And I think I have given kind of guidance that it will be at least three-years. So from that perspective that should alleviate any near-term terms about funding.

Alright. Thank you very much for taking my questions.

We will take our next question from Gena Wang with Barclays. Please go ahead.

Hi, this is [Sheldon] (Ph) now for Gena. We have two, one on the CF program, another one on the BARDA agreements. For the CF program, you show the data from F508 del patients BC cell line. So in your Phase 1 trial on from the CTA, what patient population are you going to evaluate first, because I suppose the mRNA therapy is most potent in the class one patient, which are not addressable by the current drugs. So could you share your thoughts on the target patient population in Phase 1 and beyond? And my second question is on the BARDA award. So you mentioned that the 63.2 million is going to be spread out over three-years. So at what pace or what cadence should we expect those milestones and because it also covers the pandemic flu, is there an overlap with the CSL collaboration or we receive benefit from both.

Great. There is a few questions there. I will begin to address the first question that the Phase 1 trial for CF is intended to involve healthy volunteers. And the strategic thinking there is it allows us to escalate the dose and identify the dose parameters quickly and therefore lock in the dose quickly. And then when we transition to patients, we will be more optimistic about the specific dose. With respect to - I can address the BARDA related questions as well. But Pad anything to add or did I capture - did I address the question on the CTL Phase I question?

Yes, exactly as Joe mentioned. So we are going into healthy volunteers. And that is the regulatory feedback that we received. And based on that regulatory feedback, we are going into healthy volunteers to pick the dose. And then of course, on our Phase I, we will be looking into patients and that will be a multiple dose study.

Yes. And with respect to the next question on, yes, it is correct that, that 63 million value award is spread over three-years. But this is a cost reimbursement structure that is very typical that you see in BARDA agreements to agreements with the United States government. So there is nothing out of the ordinary with respect to how it is reimbursed. And was there a third question? I think that is it.

No. I mean, is this flu pandemic program also one of the indication that covered by the CSL collaboration, so are you going to also receive reimbursement from CSL?

No, the BARDA agreement is considered separate. I mentioned that, that CSL will - I’m referring to my notes in the script, but just give me a moment. I mentioned that because I want to be careful in my messaging and see us just entering a new partnership. But there it is, that the CSL collaboration agreement allows for Acrturus to perform its obligations under the BARDA contract just to give clear guidance there. So it is a separate agreement. We have a relationship with the government. We can operate accordingly. And ailment on the CSL R&D call recently said that they would approach working with Acrturus, as using the best of both companies’ technologies to what is advanced in each of the vaccine fields.

Got it, very helpful. Thank you so much.

Thank you. We will take our next question from Yale Jen with Laidlaw and Company. Please go ahead.

Good afternoon and thanks for taking the question. I just want to be clear that 154 will be the same or similar COVID vaccine for the CSL or CSL will start over with a new version of the COVID vaccine?

Well, you can imagine all of the above. But the strategic thinking and direction and messaging pertaining to ARCT-154 and any sort of future derivatives is going to be communicated by CSL. So would be inappropriate for me to provide guidance with respect to their strategic thinking on any future derivatives.

Okay. Maybe just one more follow-up here, which is the ARCT-032, how should we think about based on the current preclinical data comparing to some other mRNA based CF treatment maybe earlier one or any comp comparisons you can make from that.

Yes, I will start and allow Pad to fill in so many gaps or provide any additional comments. But we have some unique aspects to our CF therapeutic. It is the only one that I know that utilizes the LUNAR delivery technology. We have applied our proprietary and trade secret know-how on the manufacturing of this of the messenger RNA, so it is suitably pure for inhalation applications. And then with respect to the data we have showed data in healthy animals in mice, rats, ferrets, and primates. And this new data set is a fifth animal model, and this time it is a CF ferret model, and I think we are the only ones to have this collective set of data. But Pad, anything else to add with how this differentiates compared to other.

Yes. From the data that we have seen at least it generated in the in-vitro model, we look very, very promising. Obviously, we have restored the CFTR expression to almost wild type levels. So, that data is pretty encouraging. We haven’t seen similar data sets with others yet.

Okay, great that is very helpful. And congrats on the development.

Okay. Thank you Yale.

We will take our next question from Yanan Zhu with Wells Fargo Securities. Please go ahead.

Hi thanks for taking my questions. So first on the COVID-19 or rather the CSL milestones is it reasonable to assume that the weight across different the five different programs might be different and the COVID-19 may be weighted more heavily in a milestones? And if so, could you share a proportion for that? And then also on the new program that you are talking you plan on announcing sometime next year. I’m wondering what features are you looking at in making the decision, in terms of the biology, whether de-risked targets or novel targets and any other considerations that goes into that decision? Thanks.

Sure, yes two good questions. Thanks. So with respect to the first one, I will reiterate that there is $1.3 billion in development milestones across five programs and while we haven’t disclosed and will not disclose the relative amounts of each of those milestones and timelines. It is true that the COVID-19 vaccine is the most advanced and has the shortest development timeline remaining to potential approval, of course, as being the most advanced of those five programs. But other than that, we are not disclosing any additional information. With respect to the new targets that we are seriously considering to add, to deliver therapeutic targets, we hold those cards very close to our chest. We understand the value and the specific value of our therapeutic technologies. We have come to realize that the LUNAR technology is exceptional at delivering large RNA molecules and that the technology is biodegradable and non-accumulating and the applicability of this technology through systemic administrations and inhaled administrations. So we are going to definitely leverage our technology differentiation with the LUNAR delivery technology. But with respect to specific guidance, it is too early to do that. There is other competitors as you can appreciate in this space. So we will be strategic when we provide more hints there.

Got it. Thank you for the color. If I may add a question for the CF program, with all the animal models you have studied, how in terms of multiple dosing what is the experience therein terms of any potential immune reactions after multiple doses or antidrug antibodies and things of that sort. Thank you.

Yes. Well, I will start with the most advanced animal human beings, and then I will turn the time over to Pad to discuss some more collective preclinical evaluations in general of the LUNAR franchise. But I want to reiterate that in our Phase 1 study that we -- our therapeutic has now been injected in Phase 1 and Phase 1B, that is 29 people have received the ARCT-810. And in the Phase 1 studies, we actively investigated and looked at lipid decomposition and we observed that there was no lipids remaining in the plasma after 48-hours. So that was viewed very positively in humans. With respect to other safety parameters or the immunogenic - I will turn the time over to Pad.

Yes. We have talked about this in the past. You might recall that we shared data that of our nine-month safety data - the nine-month tox data for the OTC program. Essentially, we gave weekly dosing for nine months in non-human primates, and we didn’t see any loss in activity of the delivered protein. So that was pretty encouraging for us. Showing the LUNAR was at least pre-clinically it showed quite a promise.

Got it. Thank you for the color.

Thanks.

At this time, there are no further questions in the queue. I would like to turn the conference back to your presenters for an additional or closing remarks.

No closing remarks. Just thanks for participating on the call, and if there is any remaining questions, please reach out to the team and we will get back to you right away. Thanks to everyone. Goodnight.

Ladies and gentlemen, this concludes today’s conference. We appreciate your participation. You may now disconnect.